4.5 Article

Occupational exposures and incidence of chronic bronchitis and related symptoms over two decades: the European Community Respiratory Health Survey

期刊

OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
卷 76, 期 4, 页码 222-229

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/oemed-2018-105274

关键词

-

资金

  1. Australia: Asthma Foundation of Victoria
  2. Belgium: Belgian Science Policy Office
  3. Belgium: National Fund for Scientific Research
  4. Estonia: Estonian Science Foundation [1088]
  5. France: Ministere de la Sante
  6. France: Glaxo France
  7. France: Insitut Pneumologique d'Aquitaine
  8. France: Contrat de Plan Etat-Region Languedoc-Rousillon
  9. France: CNMATS
  10. France: CNMRT [90MR/10, 91AF/6]
  11. France: Ministre delegue de la sante
  12. France: RNSP, France
  13. GSF, Germany: Bundesminister fur Forschung und Technologie
  14. Italy: Ministero dell'Universita e della Ricerca Scientifica e Tecnologica
  15. Italy: CNR
  16. Italy: Regione Veneto grant RSF [381/05.93]
  17. Norway: Norwegian Research Council [101422/310, 214123]
  18. Spain: Fondo de Investigacion Sanitaria [91/0016-060-05/E, 92/0319, 93/0393, PS09/02457, PS09/00716 09/01511, PS09/02185, PS09/03190]
  19. Spain: Hospital General de Albacete
  20. Spain: Hospital General Juan Ramon Jimenez
  21. Spain: Direccion Regional de Salud Publica (Consejeria de Sanidad del Principado de Asturias)
  22. Spain: CIRIT [1997 SGR 00079]
  23. Spain: Servicio Andaluz de Salud
  24. Sweden: The Swedish Medical Research Council
  25. Sweden: Swedish Heart Lung Foundation
  26. Sweden: Swedish Association Against Asthma and Allergy
  27. Switzerland: Swiss National Science Foundation [4026-28099]
  28. UK: National Asthma Campaign
  29. UK: British Lung Foundation
  30. UK: Department of Health
  31. UK: South Thames Regional Health Authority
  32. USA: US Department of Health, Education and Welfare Public Health Service [2 S07 RR05521-28]
  33. Australia: National Health and Medical Research Council
  34. Belgium: Antwerp: Fund for Scientific Research [G.0402.00]
  35. Belgium: University of Antwerp
  36. Belgium: Flemish Health Ministry
  37. Estonia: Tartu Estonian Science Foundation [4350]
  38. France: (All) Programme Hospitalier de Recherche Clinique-Direction de la Recherche Clinique (DRC) de Grenoble 2000 [2610]
  39. France: Ministry of Health
  40. France: Ministere de l'Emploi et de la Solidarite
  41. France: Direction Generale de la Sante
  42. France: Centre Hospitalier Universitaire (CHU) de Grenoble
  43. Bordeaux: Institut Pneumologique d'Aquitaine
  44. Grenoble: Comite des Maladies Respiratoires de l'Isere Montpellier: Aventis (France)
  45. Grenoble: Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon
  46. Paris: Union Chimique Belge- Pharma (France)
  47. Paris: Aventis (France)
  48. Germany: Erfurt GSF-National Research Centre for Environment and Health
  49. Germany: Deutsche Forschungsgemeinschaft [FR1526/1-1]
  50. Hamburg: GSF-National Research Centre for Environment and Health
  51. Iceland: Reykjavik
  52. Iceland: Icelandic Research Council
  53. Iceland: Icelandic University Hospital Fund
  54. Italy: Pavia GlaxoSmithKline Italy
  55. Italy: Italian Ministry of University and Scientific and Technological Research (MURST)
  56. Italy: Local University Funding for Research 1998 and 1999
  57. Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy)
  58. Turin: Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico-Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte Verona: Ministero dell'Universita e della Ricerca Scientifica (MURST)
  59. Turin: Glaxo Wellcome
  60. Norway: Bergen: Norwegian Research Council
  61. Norway: Bergen: Norwegian Asthma and Allergy Association
  62. Norway: Bergen: Glaxo Wellcome
  63. Norway: Bergen: Norway Research Fund
  64. Spain: Fondo de Investigacion Santarias [97/0035-01, 99/0034-01, 99/0034 02]
  65. Spain: Hospital Universitario de Albacete
  66. Spain: Consejeria de Sanidad
  67. Barcelona: Sociedad Espanola de Neumologia y Cirugia Toracica
  68. Barcelona: Public Health Service [R01 HL62633-01]
  69. Barcelona: Fondo de Investigaciones Santarias [97/0035-01, 99/0034-01, 99/0034-02]
  70. Barcelona: Consell Interdepartamentalde Recerca i Innovacio Tecnologica [1999SGR 00241]
  71. Barcelona: Instituto de Salud Carlos III
  72. Red de Centros de Epidemiologia y Salud Publica [C03/09]
  73. Redde Basesmoleculares y fisiologicas de las Enfermedades Respiratorias [C03/011]
  74. Red de Grupos Infancia y Medio Ambiente [G03/176]
  75. Huelva: Fondo de Investigaciones Santarias [97/0035-01, 99/0034-01, 99/0034-02]
  76. Galdakao: Basque Health Department
  77. Oviedo: Fondo de Investigaciones Sanitaria [99/0034-01, 99/0034-02, 97/0035-02, 97/0035, 99/0034-04, 99/0034-06, 99/350, 99/0034-07]
  78. Oviedo: European Commission [EU-PEAL PL01237]
  79. Oviedo: Generalitat de Catalunya [CIRIT 1999 SGR 00214]
  80. Oviedo: Hospital Universitario de Albacete
  81. Oviedo: Sociedad Espanola de Neumologia y Cirugia Toracica [SEPAR R01 HL62633-01]
  82. Oviedo: Red de Centros de Epidemiologia y Salud Publica [C03/09]
  83. Oviedo: Red de Bases moleculares y fisiologicas de las Enfermedades Respiratorias [C03/011]
  84. Oviedo: Red de Grupos Infancia y Medio Ambiente [97/0035-01, 99/0034-01, 99/0034-02, G03/176]
  85. Sweden: Goteborg: Swedish Heart Lung Foundation
  86. Sweden: Goteborg: Swedish Foundation for Health Care Sciences and Allergy Research
  87. Sweden: Goteborg: Swedish Asthma and Allergy Foundation
  88. Sweden: Goteborg: Swedish Cancer and Allergy Foundation
  89. Sweden: Goteborg: Swedish Council for Working Life and Social Research (FAS)
  90. Sweden: Umea: Swedish Heart Lung Foundation
  91. Sweden: Umea: Swedish Foundation for Health Care Sciences and Allergy Research
  92. Sweden: Umea: Swedish Asthma and Allergy Foundation
  93. Sweden: Umea: Swedish Cancer and Allergy Foundation
  94. Sweden: Umea: Swedish Council for Working Life and Social Research (FAS)
  95. Sweden: Uppsala: Swedish Heart Lung Foundation
  96. Sweden: Uppsala: Swedish Foundation for Health Care Sciences and Allergy Research
  97. Sweden: Uppsala: Swedish Asthma and Allergy Foundation
  98. Sweden: Uppsala: Swedish Cancer and Allergy Foundation
  99. Sweden: Uppsala: Swedish Council for Working Life and Social Research (FAS)
  100. Switzerland: Basel Swiss National Science Foundation
  101. Switzerland: Swiss Federal Office for Education and Science
  102. Switzerland: Swiss National Accident Insurance Fund
  103. UK: Ipswich: Asthma UK
  104. USA: Portland: American Lung Association of Oregon
  105. USA: Portland: Northwest Health Foundation
  106. USA: Portland: Collins Foundation
  107. USA: Portland: Merck Pharmaceutical
  108. Belgium: Antwerp South, Antwerp City: Research Foundation Flanders (FWO) [G.0.410.08.N.10]
  109. Estonia: the Estonian Ministry of Education [Tartu-SF0180060s09]
  110. France: (All) Ministere de la Sante
  111. Programme Hospitalier de Recherche Clinique (PHRC), National 2010
  112. Bordeaux: INSERM U897
  113. Bordeaux: Universite Bordeaux Segalen
  114. Grenoble: Comite Scientifique AGIR adom 2011
  115. Paris: Agence Nationale de la Sante
  116. Paris: domaine d'interet majeur (DIM)
  117. Germany: Erfurt: German Research Foundation [HE 3294/10-1]
  118. Hamburg: German Research Foundation [MA 711/6-1, NO 262/7-1]
  119. Iceland: Landspitali University Hospital Research Fund
  120. Iceland: University of Iceland Research Fund
  121. Iceland: ResMed Foundation, California, USA
  122. Iceland: Orkuveita Reykjavikur (geothermal plant)
  123. Iceland: Vegageroin (the Icelandic Road Administration, ICERA)
  124. Italy: Italian Ministry of Health
  125. Italy: Chiesi Farmaceutici
  126. Cariverona Foundation
  127. Education Ministry (MIUR)
  128. Norway: Western Norway Regional Health Authorities [911631]
  129. Norway: Bergen Medical Research Foundation
  130. Spain: Sociedad Espanola de Neumologia y Cirurgia Toracica [SEPAR 1001/2010]
  131. Sweden: Swedish Heart and Lung Foundation
  132. Sweden: Swedish Asthma and Allergy Association
  133. Sweden: Swedish Association Against Lung and Heart Disease
  134. Fondo de Investigacion Sanitaria [PS09/02457]
  135. Barcelona: Fondo de Investigacion Sanitaria [FIS PS09/00716]
  136. Galdakao: Fondo de Investigacion Sanitaria [FIS 09/01511]
  137. Huelva: Fondo de Investigacion Sanitaria [FIS PS09/02185]
  138. Huelva: Servicio Andaluz de Salud Oviedo: Fondo de Investigacion Sanitaria [FIS PS09/03190]
  139. Swedish Research Council for Health, Working Life and Welfare (FORTE)
  140. Goteborg: Swedish Council for Working Life and Social Research
  141. Vasterbotten Country Council ALF grant
  142. Switzerland: The Swiss National Science Foundation [33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099]
  143. Federal Office for Forest, Environment and Landscape
  144. Federal Office of Public Health
  145. Federal Office of Roads and Transport
  146. Canton's Government of Aargan
  147. Canton's Government of Basel-Stadt
  148. Canton's Government of Basel-Land
  149. Canton's Government of Geneva
  150. Canton's Government of Luzern
  151. Canton's Government of Ticino
  152. Canton's Government of Valais
  153. Canton's Government of Zurich
  154. Swiss Lung League
  155. Canton's Lung League of Basel Stadt/Basel
  156. Canton's Lung League of Landschaft
  157. Canton's Lung League of Geneva
  158. Canton's Lung League of Ticino
  159. Canton's Lung League of Valais
  160. Canton's Lung League of Zurich
  161. SUVA
  162. Freiwillige Akademische Gesellschaft
  163. UBS Wealth Foundation
  164. Talecris Biotherapeutics
  165. Abbott Diagnostics
  166. European Commission [018996]
  167. Wellcome Trust [WT 084703MA]
  168. UK: Medical Research Council [92091]
  169. National Institute for Health Research through the Primary Care Research Network
  170. Medical Research Council [92091]
  171. Australia: Allen and Hanbury's
  172. Paris: Glaxo France
  173. Hamburg: Deutsche Forschungsgemeinschaft [MA 711/4-1]
  174. UK: Norwich: Asthma UK
  175. Paris: Region Ile de France
  176. Medical Research Council [G0901214] Funding Source: researchfish
  177. MRC [G0901214, MR/L01341X/1] Funding Source: UKRI

向作者/读者索取更多资源

Objectives Chronic bronchitis (CB) is an important chronic obstructive pulmonary disease (COPD)-related phenotype, with distinct clinical features and prognostic implications. Occupational exposures have been previously associated with increased risk of CB but few studies have examined this association prospectively using objective exposure assessment. We examined the effect of occupational exposures on CB incidence in the European Community Respiratory Health Survey. Methods Population samples aged 20-44 were randomly selected in 1991-1993, and followed up twice over 20 years. Participants without chronic cough or phlegm at baseline were analysed. Coded job histories during follow-up were linked to the ALOHA Job Exposure Matrix, generating occupational exposure estimates to 12 categories of chemical agents. Their association with CB incidence over both follow-ups was examined with Poisson models using generalised estimating equations. Results 8794 participants fulfilled the inclusion criteria, contributing 13 185 observations. Only participants exposed to metals had a higher incidence of CB (relative risk (RR) 1.70, 95% CI 1.16 to 2.50) compared with non-exposed to metals. Mineral dust exposure increased the incidence of chronic phlegm (RR 1.72, 95% CI 1.43 to 2.06). Incidence of chronic phlegm was increased in men exposed to gases/fumes and to solvents and in women exposed to pesticides. Conclusions Occupational exposures are associated with chronic phlegm and CB, and the evidence is strongest for metals and mineral dust exposure. The observed differences between men and women warrant further investigation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据